A global shortfall in radiotherapy resources has led to millions of unnecessary deaths, but investing in radiotherapy services could bring economic benefits of up to $365 billion over the next 20 years. Access to radiotherapy is currently unacceptably low, especially in Africa, where most countries have no facilities.
The study found that everolimus improved progression-free survival by 52% and increased median progression-free survival by over seven months in patients with advanced, nonfunctional neuroendocrine tumors. The treatment was well-tolerated, with common side effects including aphthous ulceration, rash, diarrhea, fatigue, and infections.
Researchers found molecular differences in younger-onset CRC tumors related to epigenetics and gene expression. This discovery could lead to tailored treatments for younger patients. The study analyzed genetic mutations in 126 under-50 patients and 368 over-50 patients, revealing distinctive patterns.
The study found substantial differences in surgery, hormone therapy, and chemotherapy use among European countries for elderly breast cancer patients. Treatment approaches varied depending on the stage of the disease, with some countries omitting surgery or using more chemotherapy than others.
A new study reveals that brain metastases carry distinct genetic profiles compared to primary tumors, suggesting divergent evolutionary pathways and potential sensitivity to targeted therapy drugs. The research identifies clinically significant mutations in over half of patients' brain metastases.
Research highlights significant disparities in cancer care among migrants and refugees, with lower rates of early diagnosis and treatment. The European Society for Medical Oncology calls for policy changes to address these disparities and improve access to quality cancer care.
A new report highlights progress in treating childhood cancers, but notes that many survivors face long-term treatment-related side effects. The European Society for Paediatric Oncology proposes solutions to tackle these issues, including improving access to new drugs and enhancing collaboration with adult oncology.
A new study examines the effects of hearing loss on infant development, while another investigation looks at how older adults are impacted when their hearing begins to fade. The research aims to provide insights into various age groups' experiences with hearing loss and its treatment.
Researchers found that brain metastases share some genetic similarities with the primary tumor but also have key differences, including potential drug targets in over half of patients. Genetic analysis of brain metastases could reveal new treatment options, especially when compared to primary tumors.
A large prospective post-commercialization study in patients with advanced soft tissue sarcoma (STS) in Europe confirms the long-term anticancer activity of YONDELIS® (trabectedin). The median progression-free survival was 5.5 months, and durable responses were observed in 18 patients still on treatment.
Researchers have shown that the mTOR inhibitor everolimus can delay tumour growth among both gastrointestinal and lung NETs, particularly for patients with lung tumours. The trial included 302 patients and found a 52% reduction in progression or death risk and a clinically meaningful improvement in median progression-free survival.
Patients with recurrent lung cancer who undergo a CT-based follow-up program after surgery experience significantly improved post-surgery survival rates. The study analyzed 391 patients and found that the number of patients alive four years after surgery increased from 54% to an estimated 68%.
The ESMO Global Opioid Policy Initiative reveals disparities in opioid access across the globe, with the Middle East, Latin America, and Asia showing limited access to essential pain relieving medication. The addition of new Designated Centres brings polices tailored to patient needs, promoting a multidisciplinary approach to cancer care.
A phase III trial has shown that 177Lu-DOTATATE significantly improves progression-free survival in patients with mid-gut neuroendocrine tumours, a rare and hard-to-treat disease. The treatment outperforms standard care in terms of time without disease progression.